Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

FDA Approval Sought for Erdafitinib in Locally Advanced or Metastatic FGFR3+ Urothelial Carcinoma

August 29th 2023

A supplemental new drug application seeking the full approval of erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma harboring susceptible FGFR3 alterations who progressed during or following at least 1 line of a PD-1/PD-L1 inhibitor in the locally advanced or metastatic setting or within 12 months of neoadjuvant or adjuvant therapy, has been submitted to the FDA.

Radical Cystectomy or Bladder Preservation: Understanding Optimal Therapy for Locally Advanced Bladder Cancer

August 28th 2023

Neil Desai, MD, MHS, expands on the need for further research regarding potential treatment strategies for patients with locally advanced, nonmetastatic muscle-invasive bladder cancer who may not benefit from standard approaches.

Dr Petrylak on Sequencing Questions in FGFR2/3-Altered Metastatic Urothelial Cancer

August 24th 2023

Daniel P. Petrylak, MD, discusses sequencing treatment selections in patients with FGFR2/3-altered metastatic urothelial cancer.

Dr Sonpavde on the Importance of Utilizing Precision Medicine in Bladder Cancer

August 22nd 2023

Guru P. Sonpavde, MD, discusses the importance of utilizing precision medicine in bladder cancer, and highlights the rationales and designs of the ongoing phase 3 EV-302 and AMBASSADOR trials.

Enfortumab Vedotin Plus Pembrolizumab Sustains Long-Term Benefit in Metastatic Urothelial Carcinoma

August 22nd 2023

Shilpa Gupta, MD, expands on the updated results from EV-103 in patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin, and details the next steps for investigating the combination of enfortumab vedotin plus pembrolizumab in the ongoing phase 3 EV-302 trial.

Dr Grivas on Addressing Unmet Needs in Urothelial Cancer

August 18th 2023

Petros Grivas, MD, PhD, discusses several unmet needs within urothelial cancer, as well as how to potentially ameliorate them.

Dr Sonpavde on the Future of Treating Bladder Cancer

August 14th 2023

Guru P. Sonpavde, MD, discusses the future of bladder cancer treatment, including potential novel targets and further research with immunotherapy and antibody-drug conjugates.

Dr Li on the Rationale for Evaluating CG0070 Plus Pembrolizumab in BCG-Unresponsive NMIBC

August 7th 2023

Roger Li, MD, expands on the mechanism of action for the combination of CG0070 and pembrolizumab, and discusses the rationale for investigating the regimen's synergy in patients with non–muscle invasive bladder cancer who are unresponsive to Bacillus Calmette-Guérin.

Ongoing Trials Underscore Need for Further Precision Medicine Approaches in Bladder Cancer

August 7th 2023

Guru P. Sonpavde, MD, discusses key data presented from the phase 3 THOR and SWOG S1011 studies at the 2023 ASCO Annual Meeting, and details ongoing trials that could help advance precision medicine approaches for patients with bladder cancer.

Mitomycin Gel May Have a Place in Chemo-Ablative Cytoreduction of Higher-Volume, Low-Grade UTUC

August 1st 2023

Patients with low-grade upper tract urothelial carcinoma experienced similar rendered disease free rates, regardless of surgery type or tumor volume, following treatment with mitomycin for pyelocalyceal solution.

Dr Sonpavde on the Results of the SWOG S1011 Trial in MIBC

July 31st 2023

Guru P. Sonpavde, MD, discusses results from the phase 3 SWOG S1011 trial conducted in patients with muscle-invasive bladder cancer.

UGN-102 Improves Survival, Elicits CRs in Low-Grade, Intermediate-Risk NMIBC

July 27th 2023

Treatment with UGN-102 with or without transurethral resection of bladder tumors led to an improvement in disease-free survival compared with TURBT alone in patients with low-grade, intermediate-risk non–muscle-invasive bladder cancer.

Dr Galsky on the Efficacy of Adjuvant Nivolumab in the CheckMate 274 Trial in mUC

July 20th 2023

Matthew Galsky, MD, discusses how updated findings from the phase 3 CheckMate 274 study confirm the efficacy of adjuvant systemic immunotherapy in metastatic urothelial carcinoma.

Dr Gupta on Criteria for the EV-103 Trial in Advanced Urothelial Cancer

July 13th 2023

Shilpa Gupta, MD, discusses the enrollment criteria used for the phase 1/2 EV-103 trial in patients with locally advanced or metastatic urothelial carcinoma, and highlights next steps for the investigation of the frontline combination of enfortumab vedotin and pembrolizumab in the phase 3 EV-302 trial.

First-line Enfortumab Vedotin Plus Pembrolizumab Has Durable Activity in Urothelial Carcinoma

July 13th 2023

Responses achieved with enfortumab vedotin plus pembrolizumab were found to be rapid and durable in patients with previously untreated locally advanced or metastatic urothelial carcinoma who were cisplatin ineligible.

First-line Nivolumab Plus Chemo Provides Survival Benefit in Metastatic Urothelial Carcinoma

July 11th 2023

Frontline treatment with the combination of nivolumab and cisplatin-based chemotherapy, followed by nivolumab monotherapy, led to a statistically significant improvement in PFS and OS vs standard cisplatin-based chemotherapy regimens alone in previously untreated, cisplatin-eligible patients with unresectable or metastatic urothelial carcinoma.

Dr Galsky on Atezolizumab Plus Chemotherapy in Metastatic Urothelial Carcinoma

July 10th 2023

Matthew Galsky, MD, discusses final results from the phase 3 IMvigor130 trial in patients with metastatic urothelial cancer.

Neoadjuvant Enfortumab Vedotin Continues to Elicit Encouraging Antitumor Activity in MIBC

July 10th 2023

Single-agent enfortumab vedotin in the neoadjuvant setting had substantial antitumor activity and a high event-free survival rate with a manageable toxicity profile in patients with cisplatin-ineligible muscle-invasive bladder cancer.

Disitamab Vedotin Plus Toripalimab Elicits Responses, Safety in Metastatic Urothelial Carcinoma

July 4th 2023

The combination of disitamab vedotin with toripalimab generated responses and displayed a manageable safety profile in patients with locally advanced or metastatic urothelial carcinoma, irrespective of HER2 expression.

Post-Hoc Analysis Confirms Safety of Maintenance Avelumab in Urothelial Carcinoma

July 3rd 2023

The addition of first-line maintenance avelumab to best supportive care has sustained tolerability in patients with advanced urothelial carcinoma.